Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2010. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on specific share transactions rather than general financial performance.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The only reported activity is an increase in share interests by specific individuals through the GlaxoSmithKline Annual Investment Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It strictly details the re-investment of dividends paid on April 8, 2010, into Ordinary shares purchased on April 14, 2010, at a price of £12.80 per share.
Important Facts for Investors
- Dr. M M Slaoui increased their interest by 340 Ordinary shares.
- Mr. M Dunoyer increased their interest by 164 Ordinary shares.
- The shares were purchased at £12.80 per share.
- The transaction resulted from the re-investment of dividends paid on April 8, 2010.
- This filing does not contain financial statements or operational updates.